This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The WENBIT study by Dr Ebbing and colleagues¹ appears to refute the hypothesis of homocysteine as a cardiovascular risk factor. However, some important aspects were not considered in the article's discussion.

Homocysteine is a long-term risk factor. In the Gothenburg study,² women with a high homocysteine level showed a higher mortality only after a follow-up of more than 15 years. Thus, short-term follow-up after cardiovascular events will probably not be able to demonstrate a benefit of B vitamins.

Furthermore, there seems to be no continuous correlation between homocysteine and cardiovascular risk below a threshold of homocysteine level of 12 µmol/L.² In prospective studies, only participants in the highest quintile of baseline homocysteine had a significantly increased risk.³ In the WENBIT study, the mean homocysteine level at baseline was so low (approximately 11 µmol/L) that this would not be expected to act as a risk factor at all. . . . [Full Text of this Article]

Johannes Scholl, MD
scholl@preventionfirst.de
Prevention First–Private Practice for Preventive Medicine
Munich, Germany

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial
Marta Ebbing, Øyvind Bleie, Per Magne Ueland, Jan Erik Nordrehaug, Dennis W. Nilsen, Stein Emil Vollset, Helga Refsum, Eva Kristine Ringdal Pedersen, and Ottar Nygård
JAMA. 2008;300(7):795-804.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
Gian Paolo Rossi, Teresa Maria Seccia, and Achille C. Pessina
JAMA. 2008;300(24):2852.
EXTRACT | FULL TEXT  

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
George Ntaios, Christos Savopoulos, and Apostolos Hatzitolios
JAMA. 2008;300(24):2852-2853.
EXTRACT | FULL TEXT  

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease—Reply
Marta Ebbing, Per Magne Ueland, and Ottar Nygård
JAMA. 2008;300(24):2853-2854.
EXTRACT | FULL TEXT